Ipamorelin Reconstitution Chart (Every Vial Size)

Overview of Ipamorelin in Preclinical Research

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) classified as a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. In animal models and cell culture assays, Ipamorelin binds specifically to the growth hormone secretagogue receptor (GHS-R1a). Preclinical studies suggest that Ipamorelin induces a selective, pulsatile release of growth hormone (GH) without causing significant elevations in plasma cortisol or prolactin levels, distinguishing it from earlier-generation secretagogues.

To achieve accurate concentrations in bioassays and animal trials, researchers must reconstitute lyophilized Ipamorelin using precise volume-to-mass ratios. Because lyophilized peptide cakes are measured by total dry mass (typically 2mg, 5mg, or 10mg), calculating the volume of diluent added is essential for establishing standardized working solutions measured in milligrams per milliliter (mg/mL) or micrograms per volumetric division (mcg/unit).

Comprehensive Ipamorelin Reconstitution Chart

The following table provides standard concentration reference metrics across common laboratory vial sizes (2mg, 5mg, and 10mg) when reconstituted with specified volumes of Bacteriostatic Water (0.9% benzyl alcohol) or Sterile 0.9% Sodium Chloride. Volumetric metrics are detailed both per milliliter (mg/mL) and per 0.1 mL aliquot (equivalent to 10 graduations on a standard 100-unit laboratory syringe).

| Vial Mass | Diluent Volume | Final Concentration (mg/mL) | Mass per 0.01 mL (1 Unit) | Mass per 0.1 mL (10 Units) | | :--- | :--- | :--- | :--- | :--- | | **2 mg** | 1.0 mL | 2.0 mg/mL | 20 mcg | 200 mcg | | **2 mg** | 2.0 mL | 1.0 mg/mL | 10 mcg | 100 mcg | | **2 mg** | 3.0 mL | 0.67 mg/mL | 6.7 mcg | 67 mcg | | **5 mg** | 1.0 mL | 5.0 mg/mL | 50 mcg | 500 mcg | | **5 mg** | 2.5 mL | 2.0 mg/mL | 20 mcg | 200 mcg | | **5 mg** | 5.0 mL | 1.0 mg/mL | 10 mcg | 100 mcg | | **10 mg** | 2.0 mL | 5.0 mg/mL | 50 mcg | 500 mcg | | **10 mg** | 2.5 mL | 4.0 mg/mL | 40 mcg | 400 mcg | | **10 mg** | 5.0 mL | 2.0 mg/mL | 20 mcg | 200 mcg | | **10 mg** | 10.0 mL | 1.0 mg/mL | 10 mcg | 100 mcg |

This volumetric framework ensures laboratory technicians can easily convert total mass into target concentrations required for micro-dosing protocols in preclinical animal models or microfluidic culture systems. For automated calculations across variable volumes, reference the PX1 reconstitution calculator.

Mathematical Reconstitution Formula & Worked Examples

Calculating peptide concentration requires a simple mass-over-volume formula. Standardizing this equation prevents arithmetic errors when altering diluent volumes for specialized laboratory protocols.

Formula 1: C = M / V Where C = Concentration (mg/mL), M = Total Mass of Peptide (mg), and V = Total Volume of Diluent Added (mL).

Formula 2: Mass per Aliquot (mcg/mL) = C (mg/mL) × 1,000 Formula 3: Target Aliquot Mass (mcg) = Total Mass per Aliquot (mcg/mL) × Aliquot Volume (mL)

Worked Example 1: Reconstituting a 2mg Ipamorelin Vial with 2.0 mL Diluent A lab technician reconstitutes a 2mg vial of Ipamorelin with 2.0 mL of Bacteriostatic Water. Applying Formula 1 gives: C = 2 mg / 2.0 mL = 1.0 mg/mL. To convert to microgram mass per 0.1 mL aliquot: 1.0 mg/mL × 1,000 = 1,000 mcg/mL. Therefore, a 0.1 mL volume yields: 1,000 mcg/mL × 0.1 mL = 100 mcg.

Worked Example 2: Reconstituting a 5mg Ipamorelin Vial with 2.5 mL Diluent To establish a higher concentration for low-volume animal administration, a 5mg vial is reconstituted with 2.5 mL of solvent. Applying Formula 1 gives: C = 5 mg / 2.5 mL = 2.0 mg/mL. Converting to microgram density per 0.1 mL: 2.0 mg/mL × 1,000 = 2,000 mcg/mL. A 0.1 mL injection volume delivers: 2,000 mcg/mL × 0.1 mL = 200 mcg.

Selecting Appropriate Diluents for Laboratory Reconstitution

The choice of reconstitution solvent depends heavily on the intended experimental timeframe, target assay pH, and storage temperature. The primary diluents used in research environments include Bacteriostatic Water (0.9% benzyl alcohol preserved) and Sterile 0.9% Sodium Chloride (Normal Saline).

Bacteriostatic Water is the industry standard for multi-use research vials because the 0.9% benzyl alcohol prevents microbial growth over an extended storage period (typically up to 28 days under refrigeration at 2–8°C). Sterile 0.9% Sodium Chloride is preferred in specific cell culture assays or acute single-dose in vivo studies where benzyl alcohol could induce cytotoxic effects or interfere with membrane potential measurements.

Unpreserved Sterile Water for Injection (SWFI) should only be utilized for immediate single-use laboratory procedures. Without an antimicrobial agent, SWFI solutions must be used immediately or discarded to avoid sample contamination.

Aseptic Protocol for Reconstitution in Research Environments

Reconstitution of lyophilized peptides must take place within a certified laminar flow hood or biosafety cabinet to preserve sterility and sample integrity. Exposure to ambient lab air risks contaminating working solutions with particulate matter or bacteria.

Step 1: Sanitize the rubber stopper of the Ipamorelin vial using an isopropyl alcohol (70%) swab and allow it to air-dry completely. Step 2: Draw the target volume of diluent (e.g., 2.0 mL of Bacteriostatic Water) into a sterile laboratory syringe. Step 3: Insert the needle through the center of the rubber stopper at a slight angle. Allow the natural vacuum inside the vial to draw the diluent in slowly. If no vacuum is present, depress the plunger gradually to avoid spraying liquid directly onto the lyophilized cake. Step 4: Direct the fluid stream down the inside glass wall of the vial rather than directly onto the powder cake to minimize shear stress and protein denaturation. Step 5: Swirl the vial gently in a circular motion until the cake dissolves completely into a clear, colorless liquid. Never shake the vial violently, as mechanical agitation can induce aggregation or structural breakdown of the peptide chain.

Comparative Analysis: Ipamorelin vs. Other Growth Hormone Secretagogues

When designing comparative bioassays, researchers often evaluate Ipamorelin against other synthetic growth hormone secretagogues and growth hormone releasing hormones (GHRHs). Understanding structural and receptor selectivity differences helps define accurate baseline controls.

In preclinical literature, Ipamorelin is frequently compared with GHRP-2 and GHRP-6. While all three act as agonists at the GHS-R1a receptor, GHRP-2 and GHRP-6 frequently trigger secondary activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in measurable spikes in systemic cortisol and adrenocorticotropic hormone (ACTH). In contrast, in vitro assays show Ipamorelin exhibits high receptor selectivity, stimulating GH release without triggering significant ACTH, cortisol, or prolactin elevation.

Additionally, researchers often co-administer GHS-R agonists with GHRH analogs such as CJC-1295 No DAC to examine synergistic somatotrope activation. Combining a GHRH analog (which increases GH synthesis) with a ghrelin receptor agonist like Ipamorelin (which triggers pulsatile release) creates a dual-mechanism model commonly studied in rodent metabolic assays. Researchers can explore PX1's full catalog of secretagogues and analogs via our all peptides library.

Analytical Verification and Quality Standards (HPLC/MS)

Reconstitution calculations rely entirely on the precise mass of active peptide present in each vial. Mass variations or purity deficiencies alter final concentrations and skew quantitative data in downstream assays.

PX1 Research manufactures peptides in state-of-the-art, GMP-compliant facilities within the USA. Every production lot undergoes rigorous analytical testing at an independent, ISO 17025-accredited laboratory. Analytical protocols include High-Performance Liquid Chromatography (HPLC) to confirm peptide purity (>99%) and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF MS) to verify sequence identity and molecular weight.

Furthermore, every lot is subjected to chromogenic LAL assays to ensure endotoxin levels remain strictly below safe thresholds (<0.05 EU/mg), protecting primary cell cultures and animal models from endotoxin-induced inflammatory artifacts. Researchers can view lot-specific documentation directly on our dedicated COA page or explore high-volume supply options via our wholesale lab portal.

Storage, Handling, and Stability Guidelines

Proper handling and temperature control are critical to maintain the chemical stability of Ipamorelin before and after reconstitution. Peptide degradation typically occurs via deamidation, oxidation, or peptide backbone cleavage when exposed to thermal stress or repeated freeze-thaw cycles.

Lyophilized Powder Storage: Lyophilized Ipamorelin remains stable at room temperature for brief periods during transit (PX1 ships all orders via fast domestic carriers from CA and AZ). Upon receipt in the laboratory, lyophilized vials should be stored at -20°C for medium-term storage (up to 12 months) or -80°C for long-term storage to prevent degradation.

Reconstituted Solution Storage: Once reconstituted with Bacteriostatic Water, the liquid solution should be stored at 2°C to 8°C (36°F to 46°F) and used within 28 days. Avoid freezing reconstituted solutions unless aliquot-frozen once at -80°C; repeated freeze-thaw cycles cause significant protein aggregation and loss of potency.

Navigating Preclinical Dosing Calculations in Animal Models

Translating concentration figures from an ipamorelin reconstitution chart into active experimental parameters requires converting volumetric metrics into body-mass-adjusted dosages. In rodent models (mice and rats), dosing protocols are typically expressed in micrograms per kilogram of body weight (mcg/kg).

For instance, if an in vivo mouse model requires a 100 mcg/kg dose and the test subject weighs 25 grams (0.025 kg), the required mass per subject is 2.5 mcg. Utilizing a 2mg vial reconstituted with 2.0 mL of solvent yields a working concentration of 1.0 mg/mL (1,000 mcg/mL). To administer 2.5 mcg, the technician would administer 0.0025 mL (2.5 microliters), which may require further serial dilution with sterile 0.9% saline to achieve a manageable, high-precision injection volume (e.g., diluting 1:10 to deliver 25 microliters per subject).

Detailed protocol documentation and theoretical pathways can be evaluated across our complete research hub.